Utama › Melanoma › Minnesota › Minneapolis
Kajian klinikal Melanoma di Minneapolis, MN
12 kajian untuk Melanoma sedang mencari peserta di lokasi dalam dan sekitar Minneapolis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauh
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi jauh
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Mengambil pesertaFasa 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauh
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Mengambil pesertaFasa 3
- Allina Health Cancer Institute, Minneapolis
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Mengambil pesertaFasa 3
- University of Minnesota, Minneapolis
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Mengambil pesertaFasa 1/2
- Minnesota Oncology and Hematology PA, Minneapolis
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Mengambil pesertaFasa 2
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- dan 1 lagi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Mengambil pesertaFasa 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Mengambil pesertaFasa 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauh
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Mengambil pesertaFasa 3
- University of Minnesota Medical Center, Minneapolis
Kajian Melanoma di bandar lain
- Houston, TX59 kajian
- New York City, NY38 kajian
- Los Angeles, CA34 kajian
- Nashville, TN33 kajian
- Pittsburgh, PA31 kajian
- Boston, MA26 kajian
- Philadelphia, PA23 kajian
- San Francisco, CA22 kajian
- Durham, NC21 kajian
- Atlanta, GA21 kajian
- St. Louis, MO21 kajian
- Salt Lake City, UT21 kajian
Kajian lain di Minneapolis
- Kanser Payudara27 kajian
- Kanser Paru-paru Bukan Sel Kecil26 kajian
- Kanser Ovari24 kajian
- Kanser Prostat23 kajian
- Kanser (semua jenis)22 kajian
- Kegagalan Jantung21 kajian
- Kanser Paru-paru20 kajian
- Leukemia Mieloid Akut20 kajian
- Kanser Kolorektal19 kajian
- Kanser Endometrium18 kajian
- Penyakit Parkinson17 kajian
- Penyakit Kardiovaskular15 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.